Amneal's Generic Bimatoprost Ophthalmic Solution Approved by FDA
Amneal Pharmaceuticals has received FDA approval for a generic eye drop (bimatoprost 0.01%) used to treat high eye pressure linked to glaucoma and ocular hypertension.
/ 1680 items
#XY↓
Scholar Rock’s Apitegromab Application Declined by FDA Due to Manufacturer Issues
Scholar Rock’s potential new SMA treatment, Apitegromab, received a delay from the FDA due to manufacturing site issues, not the drug's safety or effectiveness.
HeartFlow Gets FDA Approval for Next-Gen Heart Plaque Detection Technology; Cigna Coverage 2025
HeartFlow receives FDA clearance for advanced AI-powered plaque analysis technology with 3D visualization, now covered by Cigna insurance starting October 2025.
Kodiak Sciences Gets 'Buy' Rating: What Investors Need to Know
Kodiak gets a "Buy" rating and $15 target. Final results for its 3 eye drugs are due 2026. Watch for rival Roche's data soon.
MBX Biosciences Advances Hypoparathyroidism Treatment to Phase 3
Once-weekly canvuparatide for hypoparathyroidism met its Phase 2 goal. 63% of patients achieved stable calcium and cut daily supplements. It was well tolerated and is advancing to Phase 3.
Goldman Sachs Initiates Immunome Coverage: Buy Rating
Goldman Sachs gave Immunome a "Buy" rating ($26 target). The company creates potentially best-in-class cancer drugs, including Varegacestat, which is seen as "differentiated." Key trial results are expected at the end of 2025.